Overview

Safety and Efficacy Study of KAI-1678 to Treat Pain in Subjects With Postherpetic Neuralgia

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
KAI Pharmaceuticals
Collaborator:
Trident Clinical Research Pty Ltd
Treatments:
Lidocaine
Criteria
Inclusion Criteria:

- diagnosis of PHN with pain for at least 3 months after segmental herpes zoster
eruption

- pain score at least 4 on 11-point numerical rating scale (0-10)

- stable doses of analgesic medications for at least 1 month"

Exclusion Criteria:

- diagnosis of PHN with pain for at least 3 months after segmental herpes zoster
eruption

- pain score at least 4 on 11-point numerical rating scale (0-10)

- stable doses of analgesic medications for at least 1 month"